drug · small molecule
mitapivat sulfate
Marketedupdated 3mo agoby $AGIO AGIOS PHARMACEUTICALS, INC.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval, with an approval for familial hemolytic anemia.
indications
investigational
Sickle Cell Disease
targets
Pyruvate kinase PKLR
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 17, 2027
189 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (33)
- Jul 31, 2041method-of-use (U-3782)US 11878049
- Jul 31, 2041method-of-use (U-4390)US 11878049
- Jul 31, 2041method-of-use (U-3782)US 11878049
- Jul 31, 2041method-of-use (U-3782)US 11878049
- Nov 21, 2038compositionUS 11254652
- Nov 21, 2038compositionUS 11254652
- Nov 21, 2038compositionUS 11254652
- Nov 21, 2038compositionUS 11254652
- Oct 11, 2038method-of-use (U-3321)US 11234976
- Oct 11, 2038method-of-use (U-3321)US 11234976
- Oct 11, 2038method-of-use (U-3321)US 11234976
- Apr 12, 2033method-of-use (U-3320)US 11793806
- Apr 12, 2033method-of-use (U-3320)US 11793806
- Apr 12, 2033method-of-use (U-3320)US 11793806
- Oct 26, 2032method-of-use (U-3319)US 9193701
- Oct 26, 2032method-of-use (U-3319)US 9193701
- Oct 26, 2032method-of-use (U-3319)US 9193701
- Oct 26, 2032method-of-use (U-4393)US 9193701
- May 3, 2032method-of-use (U-3320)US 10632114
- May 3, 2032method-of-use (U-4391)US 10632114
- May 3, 2032method-of-use (U-3320)US 10632114
- May 3, 2032method-of-use (U-3320)US 10632114
- May 3, 2032method-of-use (U-3319)US 9682080
- May 3, 2032method-of-use (U-3319)US 9682080
- May 3, 2032method-of-use (U-4392)US 9682080
- May 3, 2032method-of-use (U-3319)US 9682080
- May 3, 2032method-of-use (U-3319)US 9980961
- May 3, 2032method-of-use (U-3319)US 9980961
- May 3, 2032method-of-use (U-3319)US 9980961
- Feb 24, 2031compositionUS RE495824.5y
- Feb 24, 2031compositionUS RE495824.5y
- Feb 24, 2031compositionUS RE495824.5y
- Feb 24, 2031compositionUS RE495824.5y
FDA exclusivities (8)
- Feb 17, 2029ODE-392Orphan Drug (7y)2.5y
- Feb 17, 2029ODE-392Orphan Drug (7y)2.5y
- Feb 17, 2029ODE-392Orphan Drug (7y)2.5y
- Dec 23, 2028NPNP2.4y
- Feb 17, 2027NCENew Chemical Entity (5y)189d
- Feb 17, 2027NCENew Chemical Entity (5y)189d
- Feb 17, 2027NCENew Chemical Entity (5y)189d
- Feb 17, 2027NCENew Chemical Entity (5y)189d
News(4)
- Biotechs bring big launches and pharma rivalries into Q2 earnings periodWith the second quarter earnings period underway, BioSpace examines five biotechs with meaningful catalysts that analysts and investors are watching.biospace · 14d ago
- Agios axes next-gen sickle cell candidate after it fails to best Novo’s assetAgios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the…biospace · 21d ago
- Agios says adios to sickle cell program over lackluster phase 2 dataA phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase activator has failed to support continued development in sickle cell disease, leading the company to ax an indication for t…fiercebiotech · 21d ago
- Allogene CEO to step down; Agios drug fails key testDavid Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.biopharma_dive · 2mo ago
Data sources
last refreshed 51m ago
Found something off?
comments(0)
5-min edit window · permanent after that